Dr. Ernie Bowling is Chief Optometric Editor of Optometry Times. He received his Doctor of Optometry and Master of Science in Physiological Optics degrees from the UAB School of Optometry. Dr. Bowling is a Diplomate in the Primary Care Section of the American Academy of Optometry. He practices in Gadsden, AL.
Much has been written about Opternative, and I will not rehash what the product is and what it purports to do. I will say the product presents a clear and present danger to the eye health of the unsuspecting public. We can argue the merits of disruptive technology, but the bottom line is the product as currently marketed as an “eye exam” is a public health threat.
At a recent meeting I attended one of the discussions included a quick and brief outline of what is termed SWOT. SWOT stands for Strength, Weaknesses, Opportunities, and Threats. The idea here is that a scan of the internal and external environment is an important part of a strategic planning process for any business.
Point-of-care (POC) diagnostic laboratory testing is not common in eye care. This is not due to any lack of clinical need—it is rather the result of a lack of specific tests known to demonstrate diagnostic and/or treatment relevance to the optometrist and a general resistance to adopting new diagnostic technologies.
In this issue you'll find an article on clinical laboratory testing for optometry. It is my new passion. It’s something I do in my office on a daily basis, and I find it really helps me in my clinical decision-making.
In his email, Mike tackles the ongoing question in all of eye care: should I accept (or drop or keep taking) That Crappy Insurance (TCI)? Anyone in optometric practice knows exactly which ones they are.
A colleague recently forwarded an editorial from our sister publication, Ophthalmology Times. “Are medical students happy?” was penned by Chief Medical Editor Peter J. McDonnell, MD (his opinion pieces are worth an OD’s read, by the way), and he took issue with an Los Angeles Times op-ed piece from Rich Joseph, a dual MD/MBA candidate at Stanford.
Anyone who treats ocular surface disease (OSD) recognizes the important role oral antibiotics play in therapy, especially in patients with meibomian gland dysfunction (MGD). Yet the existing evidence is insufficient to conclude the effectiveness of oral antibiotic therapy, according to a report published in Ophthalmology.
One Sunday evening after a trip to Chicago, we had dinner at a Mexican restaurant we’d frequented at least a dozen times. After a quick meal, returning to the parking lot I found my truck to be the subject of what the very polite Atlanta policeman later described as a classic “smash and grab.”